TCRT Stock Explodes As Alaunos Seals Velaris Deal And $350M Raise

Alaunos Therapeutics Inc. stocks have been trading up by 10.55 percent following upbeat sentiment around its oncology pipeline prospects.

Spot the Next Big Runner

Click Here for a Millionaire's POV on Trading TCRT

SUBSCRIBE FOR ALERTS

JOIN 50,000+ ACTIVE TRADERS

Key Takeaways Traders Need To Know

Alaunos Therapeutics completed the acquisition of Velaris Therapeutics, adding ActRII-Fc ligand traps and biologics for pulmonary arterial hypertension and related cardiopulmonary diseases.
The company raised about $350M in a concurrent private placement, expected to fund operations into 2029 and multiple proof-of-concept and early regulatory milestones.
Management structured the deal via Series C non-voting convertible preferred stock, bringing in roughly $350M of new capital.
Following the acquisition and financing news, shares of TCRT spiked between about 126% and 225% on extremely heavy trading volume.
A key focus for Alaunos Therapeutics now is advancing lead candidate VLR199 for pulmonary arterial hypertension.

Live Update At 12:33:47 EDT: On Friday, October 16, 2026 Alaunos Therapeutics Inc. stock [NASDAQ: TCRT] is trending up by 10.55%! Discover the key drivers behind this movement as well as our expert analysis in the detailed breakdown below.

Quick Financial Overview

TCRT has gone from sleepy biotech to full-on momentum name in a matter of days. Alaunos Therapeutics was trading under $1 for most recent sessions, then exploded after the Velaris Therapeutics acquisition and $350M financing hit the tape. On the daily chart, TCRT ran from a close of $1.05 on 2026/10/12 to a high of $4.40 on 2026/10/14 before pulling back and closing at $2.41 on 2026/10/16. That’s a wild multi-bagger spike with a hard fade — classic low-float biotech behavior.

Under the hood, Alaunos Therapeutics is still an early-stage story. Recent quarterly revenue was only about $5,000, with a massive pretax loss margin and negative cash flow of roughly -$300,000 for the quarter ending 2026/06/30. TCRT reported just $124,000 in cash on that balance sheet and a weak current ratio of 0.8, so the $350M private placement is a complete game-changer for liquidity.

More Breaking News

Valuation-wise, the old numbers show a sky‑high price-to-sales ratio and deeply negative returns on equity and assets, which is normal for a pre‑commercial biotech. For traders, the key is that Alaunos Therapeutics now has a long runway and a new pipeline story, not that legacy fundamentals suddenly turned pretty.

Why Traders Are Watching TCRT After The Velaris Deal

The market doesn’t hand out 100%–200% moves for nothing. TCRT earned that move because Alaunos Therapeutics dropped a real catalyst: closing the Velaris Therapeutics acquisition and locking in about $350M of fresh capital via Series C non‑voting convertible preferred stock.

That deal plugs a completely new pipeline into Alaunos Therapeutics. Velaris brings ActRII‑Fc ligand traps and biologics targeting pulmonary arterial hypertension and other cardiopulmonary diseases, with VLR199 front and center. For a company that previously had minimal revenue and a thin balance sheet, this is a major pivot. TCRT is now betting its future on a defined cardiopulmonary franchise with clear clinical milestones like proof‑of‑concept and initial regulatory filings funded out to 2029.

Traders are reacting to two things at once. First, the extended cash runway dramatically cuts near‑term financing risk. Before this raise, Alaunos Therapeutics was sitting on just over $100,000 in cash and negative working capital. Now, the $350M private placement suggests institutions were willing to back the new strategy in size.

Second, TCRT turned into a momentum playground. Reports of shares surging roughly 126% to 225% on extremely heavy trading volume tell you algorithms, day traders, and swing traders all piled in. The intraday 5‑minute chart on the latest session shows a big gap and run into the $2.90–$3.00 area premarket, followed by lower highs and a fade into the $2.40s. That’s textbook “news spike, then digestion” price action. The range is still wide, liquidity is high, and Alaunos Therapeutics remains a prime candidate for secondary squeezes, failed breakouts, and big intraday opportunities.

Conclusion

For active traders, TCRT is now a completely different animal than it was a week ago. Alaunos Therapeutics transformed from a cash‑starved micro‑cap with tiny revenue into a cash‑rich development platform with a focused cardiopulmonary pipeline thanks to the Velaris Therapeutics acquisition and $350M private placement. The runway into 2029 gives management time to push VLR199 and other ActRII‑Fc programs through proof‑of‑concept and early regulatory steps.

That doesn’t remove clinical risk or valuation risk. Alaunos Therapeutics is still pre‑commercial, and every biotech trader knows trial data, regulatory feedback, and market sentiment can swing a stock like TCRT in both directions fast. The recent move from under $1 to over $4, then back to the mid‑$2s, proves how violent those swings can be.

This is where discipline matters. TCRT’s story now has real catalysts, real funding, and real liquidity, which is exactly the mix momentum traders hunt. As Tim Bohen, lead trainer with StocksToTrade says, “I focus on what a stock is doing, not what I want it to do. Let the stock prove itself before you make a move.” But as Tim Sykes always says, “The pattern is your edge, but only if you respect your rules and cut losses quickly.” Alaunos Therapeutics offers opportunity, not guarantees. Treat TCRT as a trading vehicle, study the chart, track the news, and remember this is for educational and research purposes only — not a recommendation to buy or sell.

This is stock news, not investment advice. StocksToTrade News delivers real-time stock market updates tailored to highlight the key catalysts driving short-term price movements. Our coverage is designed for active traders and investors who thrive in fast-moving markets, with a focus on volatile sectors like penny stocks, AI stocks, Robinhood stocks and other momentum plays. From earnings reports and FDA approvals to mergers, new contracts, and unusual trading volume, we break down the events that can spark significant price action.

Looking to level up your trading game? Explore StocksToTrade, the ultimate platform for traders. With powerful tools designed for swing and day trading, integrated news scanning, and even social media monitoring, StocksToTrade keeps you one step ahead.

Check out our quick startup guide for new traders!

Ready to build your watchlists? Check out these curated lists:

Once your watchlist is set, take the next step and trade with confidence using StocksToTrade’s robust platform. Don’t miss out — grab your 14-day trial for just $7 and experience the edge you need to thrive in today’s fast-paced markets.

Start Your Trial Now!